remimazolam has been researched along with Anaphylaxis* in 5 studies
1 review(s) available for remimazolam and Anaphylaxis
| Article | Year |
|---|---|
Remimazolam Anaphylaxis during Induction of General Anesthesia Confirmed by Provocation Test-A Case Report and Literature Review.
Topics: Anaphylaxis; Anesthesia, General; Benzodiazepines; Epinephrine; Female; Humans; Middle Aged | 2023 |
4 other study(ies) available for remimazolam and Anaphylaxis
| Article | Year |
|---|---|
An update on remimazolam and anaphylaxis.
Topics: Anaphylaxis; Benzodiazepines; Humans | 2023 |
Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation.
Remimazolam is an ultra-short-acting intravenous benzodiazepine, which has been used as sedative/anesthetic in procedural sedation and anesthesia. Although peri-operative anaphylaxis due to remimazolam has been reported recently, the spectrum of the allergic reactions is still not fully known.. We describe a case of anaphylaxis following remimazolam administration in a male patient undergoing colonoscopy under procedural sedation. The patient presented complex clinical signs including airway changes, skin symptoms, gastrointestinal manifestations and hemodynamic fluctuations. Different from other reported cases, laryngeal edema was the initial and main clinical feature of remimiazolam-induced anaphylaxis.. Remimazolam-induced anaphylaxis has a rapid onset and complex clinical features. This case reminds anesthesiologists should be particularly alert to the unknown adverse reactions of new anesthetics. Topics: Adult; Anaphylaxis; Benzodiazepines; Humans; Hypnotics and Sedatives; Laryngeal Edema; Male | 2023 |
Anaphylaxis following remimazolam administration during induction of anaesthesia.
Topics: Anaphylaxis; Anesthesia; Benzodiazepines; Humans; Hypnotics and Sedatives | 2022 |
Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.
Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an excipient in the remimazolam solution, and a review of drugs given during 3 anesthetics, remimazolam was identified as the probable causative agent. Although remimazolam is structurally similar to midazolam, the patient was not allergic to midazolam as demonstrated before and after anaphylaxis. This report highlights the potential risk of allergic reactions to remimazolam. Topics: Aged; Anaphylaxis; Benzodiazepines; Dextrans; Double-Blind Method; Excipients; Heart Arrest; Humans; Hypnotics and Sedatives; Male; Midazolam | 2022 |